Literature DB >> 11302748

Serine residues 110 and 114 are required for agonist binding but not antagonist binding to the melatonin MT(1) receptor.

S Conway1, E S Mowat, J E Drew, P Barrett, P Delagrange, P J Morgan.   

Abstract

Site-directed mutation of serine 110 (Ser(3.35)) and serine 114 (Ser(3.39)) in the human melatonin MT(1) receptor to alanine residues reduced ligand binding affinities of seven known melatonin receptor agonists and partial agonists by 3- to 15-fold. These mutants also displayed a relative reduction in their affinities for melatonin-mediated functional responses of 30- and 14-fold, respectively. In contrast to the observed effects of the agonists and partial agonists, the melatonin receptor antagonist luzindole was found to bind to mutants Ser(3.35)Ala and Ser(3.39)Ala with affinities equivalent to that determined for the wild-type melatonin MT(1) receptor. Luzindole was subsequently confirmed as an antagonist of melatonin-mediated functional responses for both mutant receptors. These studies have identified that in the human melatonin MT(1) receptor, Ser(3.35) and Ser(3.39), in transmembrane domain 3, are critical for the formation of the high-affinity ligand binding site for agonists and partial agonists but not for the antagonist luzindole. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11302748     DOI: 10.1006/bbrc.2001.4722

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  10 in total

1.  The study of the mechanism of binding of human ML1A melatonin receptor ligands using molecular modeling.

Authors:  A A Ivanov; A E Voronkov; I I Baskin; V A Palyulin; N S Zefirov
Journal:  Dokl Biochem Biophys       Date:  2004 Jan-Feb       Impact factor: 0.788

2.  Molecular modeling study of the mechanism of ligand binding to human melatonin receptors.

Authors:  A E Voronkov; A A Ivanov; I I Baskin; V A Palyulin; N S Zefirov
Journal:  Dokl Biochem Biophys       Date:  2005 Jul-Aug       Impact factor: 0.788

Review 3.  Update on melatonin receptors: IUPHAR Review 20.

Authors:  Ralf Jockers; Philippe Delagrange; Margarita L Dubocovich; Regina P Markus; Nicolas Renault; Gianluca Tosini; Erika Cecon; Darius P Zlotos
Journal:  Br J Pharmacol       Date:  2016-08-08       Impact factor: 8.739

4.  International Union of Basic and Clinical Pharmacology. LXXV. Nomenclature, classification, and pharmacology of G protein-coupled melatonin receptors.

Authors:  Margarita L Dubocovich; Philippe Delagrange; Diana N Krause; David Sugden; Daniel P Cardinali; James Olcese
Journal:  Pharmacol Rev       Date:  2010-07-06       Impact factor: 25.468

Review 5.  A molecular and chemical perspective in defining melatonin receptor subtype selectivity.

Authors:  King Hang Chan; Yung Hou Wong
Journal:  Int J Mol Sci       Date:  2013-09-06       Impact factor: 5.923

6.  Synthesis and functional characterization of substituted isoquinolinones as MT2-selective melatoninergic ligands.

Authors:  Yueqing Hu; King H Chan; Xixin He; Maurice K C Ho; Yung H Wong
Journal:  PLoS One       Date:  2014-12-05       Impact factor: 3.240

Review 7.  Membrane Melatonin Receptors Activated Cell Signaling in Physiology and Disease.

Authors:  Georgi Nikolaev; Ralitsa Robeva; Rossitza Konakchieva
Journal:  Int J Mol Sci       Date:  2021-12-31       Impact factor: 5.923

Review 8.  Homology models of melatonin receptors: challenges and recent advances.

Authors:  Daniele Pala; Alessio Lodola; Annalida Bedini; Gilberto Spadoni; Silvia Rivara
Journal:  Int J Mol Sci       Date:  2013-04-12       Impact factor: 5.923

9.  Structure modeling of all identified G protein-coupled receptors in the human genome.

Authors:  Yang Zhang; Mark E Devries; Jeffrey Skolnick
Journal:  PLoS Comput Biol       Date:  2006-02-17       Impact factor: 4.475

10.  GPR50 is the mammalian ortholog of Mel1c: evidence of rapid evolution in mammals.

Authors:  Laurence Dufourny; Anthony Levasseur; Martine Migaud; Isabelle Callebaut; Pierre Pontarotti; Benoit Malpaux; Philippe Monget
Journal:  BMC Evol Biol       Date:  2008-04-09       Impact factor: 3.260

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.